AI in Pharma: Hype vs. What Actually Works
Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
AI Bioweapons Risk: What Anthropic’s Report Means for Pharma
The Anthropic 2026 threat report documents a significant bioweapons risk. See what this means for pharma biosecurity, research, and AI controls.
AI Creates New Viruses? Not Quite. AI-Designed Bacteriophages
AI-designed bacteriophages show how genome models could create new antibacterial therapies while forcing pharma to rethink biological AI governance and biosecurity.
Corpus Healthy Human Protein Atlas Gives AI a Better Map
The healthy human protein atlas from Ambitious Bio could sharpen target safety checks in AI drug discovery. Explore the claims, the gaps, and the questions to ask.